Read by the brain

For a decade the incretin story was a metabolic one: hold blood sugar, quiet appetite, lower weight. The GLP-1 and GIP receptors were studied as gut-and-pancreas machinery, and the drugs built on them — tirzepatide and the rest — were weight-and-glucose drugs. Brenipatide takes the same sentence and asks whether the brain can read it.

It is, mechanically, close to familiar ground: a single peptide that agonizes both GIP and GLP-1, the same receptor pair as tirzepatide, engineered for a far longer — roughly once-monthly — reach. What is unfamiliar is the direction. Eli Lilly is leading brenipatide’s development not with obesity but with alcohol use disorder and major depression, on the bet that incretin signaling touches the brain’s reward and mood circuitry. This is a genuinely interesting wager and an almost entirely unproven one. Bullish on the science, sceptical on the page.

The premise is not arbitrary. GLP-1 receptors are expressed well beyond the pancreas — including in the mesolimbic dopamine pathway, the circuit running from the ventral tegmental area to the nucleus accumbens that encodes the pull of food, alcohol, nicotine and drugs. A signal that evolved to say “you have had enough to eat” turns out to wire into the same machinery that registers “you want more of that,” and in animals, GLP-1 agonists reduce the self-administration of several addictive substances, alcohol among them.

That is the mechanistic case for pointing an incretin drug at addiction: if the same receptor that dials down appetite also dials down the reward value of a drink or a cigarette, then a durable, brain-penetrant agonist might blunt craving the way it blunts hunger. Depression is the softer extension of the same idea — reward processing, motivation and the inflammation-and-metabolism links to mood are all plausible routes by which the signal could lift it. The biology is real. The question is how much of it survives contact with a human trial.

The strongest human evidence so far comes not from brenipatide but from its older cousin. In a small Phase 2 randomized trial, once-weekly semaglutide reduced how much alcohol people with alcohol use disorder drank in a controlled lab task, and lowered their craving, versus placebo (Hendershot et al., JAMA Psychiatry, 2025). For a first controlled test of the idea, that is an encouraging result, and it is the kind of signal that justifies a serious program.

But read the asterisk, because it is the whole scientific question in miniature. The number of drinking days did not change; what fell was the quantity consumed — and the participants also lost weight. That pattern leaves two explanations standing side by side. One is the exciting one: a specific effect on the reward circuit, craving turned down at the source. The other is more mundane: a general suppression of consumption — the same “want less, feel full, maybe faintly nauseated” effect that curbs eating, applied to a glass instead of a plate. A small trial cannot separate those, and until the field does, “GLP-1 treats addiction” is a hypothesis wearing a result’s clothing.

Against that backdrop, brenipatide’s design choices make sense. It shares tirzepatide’s two-receptor machinery but is built for an extended interval Lilly has not fully disclosed — on the order of monthly — and a drug meant to hold craving down for months, not meals, benefits from the longest possible reach and the fewest possible missed doses. Adherence is where addiction and depression treatments fail most; a once-monthly injection is a serious answer to that failure mode, independent of any reward-circuit effect.

Two honest unknowns sit inside the molecule. The first: what the GIP arm contributes in the brain is essentially uncharted — the reward evidence is mostly GLP-1 work, and why a dual GIP/GLP-1 agonist should be better than a pure GLP-1 one for addiction is an assumption, not a finding (the GIP paradox is a reminder that this receptor resists simple stories). The second: weight loss itself is a confound in a mood trial, where improvement could flow through metabolic health or inflammation rather than any direct action on the circuits of depression.

The boldest thing about brenipatide is the shape of its program. The Phase 3 RENEW trials lead in psychiatry — large studies in moderate-to-severe alcohol use disorder and in major depression as an add-on, each enrolling around a thousand participants, with Phase 2 work fanning out into bipolar disorder, schizophrenia, opioid use disorder and smoking. Obesity, the class’s home ground, is the late program here, not the lead. A company is taking a molecule straight into large, expensive psychiatric Phase 3 trials on the strength of class evidence and mechanism, ahead of a single published efficacy result for the drug itself.

That is a defensible bet and a real gamble at once. The upside is a genuinely new kind of treatment for conditions where the existing drugs are few and partial. The risk is that the human reward effect turns out to be the mundane explanation — consumption suppression that fades, or works only alongside weight loss — in which case a vast program will have been built on a signal that didn’t generalize. The results read out around 2028, and until they do, the discipline the “first human trial” headlines demand applies here in full: a Phase 3 that has enrolled is not a Phase 3 that has reported.

Brenipatide is the most interesting thing the incretin class is doing that has nothing to do with weight — and it is almost entirely a promissory note. The mechanism is real: the receptors are in the reward circuitry, and the animal and early human data point the right way. The strategy is bold: lead in psychiatry, dose monthly, go big early. And the evidence specific to this molecule is nonexistent. Hold all three together and brenipatide is what a well-reasoned, high-conviction, unproven bet looks like — the incretin sentence, written for the pancreas, carried to the clinic on the wager that the brain can read it.

• A dual GIP/GLP-1 agonist pointed at the brain. Brenipatide (LY3537031) hits tirzepatide's two receptors from one peptide, engineered for a ~monthly interval — but leads in addiction and depression, not obesity.
• The reward-circuit rationale is genuine. GLP-1 receptors sit in the mesolimbic dopamine pathway; in animals, GLP-1 agonists cut self-administration of alcohol and other drugs.
• The first human signal has a built-in caveat. Semaglutide lowered alcohol quantity and craving in a small RCT — but drinking days didn't change and weight fell. Reward-specific effect, or general consumption suppression? Unresolved.
• Monthly dosing targets the real failure mode. Adherence is where addiction and depression drugs fail; a once-monthly injection is a serious answer — independent of any craving effect. The GIP arm's brain role is uncharted.
• Phase 3 ahead of its own data. The RENEW program runs ~1,000-participant trials in alcohol use disorder and MDD, reading out ~2028, with no published brenipatide efficacy yet. A high-conviction bet, not a result.